Fig. 3: Figure showing molecular landscape, OS and LFS differences between WHO-defined MDS/MPN-RS-T and MDS/MPN-U patients with BM RS ≥ 15% (MDS/MPN-U-RS). | Blood Cancer Journal

Fig. 3: Figure showing molecular landscape, OS and LFS differences between WHO-defined MDS/MPN-RS-T and MDS/MPN-U patients with BM RS ≥ 15% (MDS/MPN-U-RS).

From: Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients

Fig. 3

A shows a heatmap displaying differences in mutational frequencies between MDS/MPN-RS-T and MDS/MPN-U-RS. SF3B1 is the only gene mutated at a significantly (*) higher frequency in the MDS/MPN-RS-T group. B shows that the Kaplan–Meier estimate of median OS (95% CI) did not differ significantly between the two groups [6 (5–9) versus 7.3 (1.8–11.4) years, P = 0.3]. Log-rank test was used to calculate the P-value.

Back to article page